<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>

Gilead Sciences Inc $ 64.51 0.52 (0.81%)

On watch
Volume:
4,557,881
Avg Vol (1m):
5,861,123
Market Cap $:
81.70 Bil
Enterprise Value $:
80.73 Bil
P/E (TTM):
13.99
P/B:
3.68
Warning! GuruFocus has detected 3 Severe warning signs with GILD. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for GILD (Gilead Sciences) from 1992 to Oct 15 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Gilead Sciences stock (GILD) PE ratio as of Oct 15 2019 is 13.99. More Details

Gilead Sciences PE Ratio (TTM) Chart

EMBED

Gilead Sciences PE Ratio (TTM) Historical Data

Total 1247
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Gilead Sciences PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-1514.0 2019-08-1314.0
2019-10-1414.0 2019-08-1213.9
2019-10-1113.9 2019-08-0914.2
2019-10-1013.7 2019-08-0814.1
2019-10-0913.4 2019-08-0713.9
2019-10-0813.4 2019-08-0613.9
2019-10-0713.6 2019-08-0513.7
2019-10-0413.6 2019-08-0214.1
2019-10-0313.5 2019-08-0114.2
2019-10-0213.4 2019-07-3114.2
2019-10-0113.7 2019-07-3014.6
2019-09-3013.8 2019-07-2914.7
2019-09-2713.6 2019-07-2614.5
2019-09-2613.7 2019-07-2514.4
2019-09-2513.9 2019-07-2414.5
2019-09-2414.0 2019-07-2314.4
2019-09-2314.3 2019-07-2214.1
2019-09-2014.4 2019-07-1914.1
2019-09-1914.3 2019-07-1814.6
2019-09-1814.3 2019-07-1714.5
2019-09-1714.4 2019-07-1614.5
2019-09-1614.3 2019-07-1514.8
2019-09-1314.4 2019-07-1214.4
2019-09-1214.4 2019-07-1114.4
2019-09-1114.8 2019-07-1014.6
2019-09-1014.6 2019-07-0914.7
2019-09-0914.4 2019-07-0814.6
2019-09-0614.1 2019-07-0514.9
2019-09-0513.9 2019-07-0415.0
2019-09-0413.7 2019-07-0315.0
2019-09-0313.7 2019-07-0214.9
2019-09-0213.8 2019-07-0114.7
2019-08-3013.8 2019-06-2814.7
2019-08-2913.8 2019-06-2714.8
2019-08-2813.8 2019-06-2614.7
2019-08-2713.7 2019-06-2515.1
2019-08-2613.7 2019-06-2415.2
2019-08-2313.6 2019-06-2115.3
2019-08-2213.9 2019-06-2015.1
2019-08-2113.9 2019-06-1915.1
2019-08-2013.8 2019-06-1815.1
2019-08-1913.9 2019-06-1714.8
2019-08-1613.7 2019-06-1414.7
2019-08-1513.6 2019-06-1314.8
2019-08-1413.7 2019-06-1214.7

Gilead Sciences PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Drug Manufacturers » Drug Manufacturers NAICS : 325412 NAICS : 2834
Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.